Log in Register
Menu

MCF7/ExeR-4 Cell Line

Invented by Dr Anne Lykkesfeldt at Danish Cancer Society

Info

Catalogue Number 152558
Antigen/Gene or Protein Targets Exemestane resistance
Parental Line MCF7
Host Human
Tissue Breast
Disease Keywords Breast Cancer
Relevance The MCF7/ExeR-4 Cell Line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors.Third generation aromatase inhibitors (AIs) have proven to be effective treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of breast cancer patients. However, a major problem is development of resistance against AIs. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the steroidal AI exemestane allows the study of the molecular basis for resistance to AIs to unravel new targets for treatment.
Production Details Exemestane-resistant cell lines were established from MCF-7 cells grown in medium with 10% NCS and 10−7 M testosterone. A culture of MCF-7 cells were treated with 10−7 M exemetane for one week, trypsinized and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with exemestane. After ~2–3 months, the isolated colonies gave rise to exemestane-resistant cell lines, which could be grown in exemestane-containing medium with a weekly split ratio of ~1:25. The MCF-7 cell line was authenticated in January 2014 by DNA profiling using short tandem repeat loci and found to be matching the genetic profile reported for the MCF-7 cell line.
Conditional No
Research Area Cancer, Drug Discovery & Development
Growth/Phenotype Keywords Breast cancer cell line resistant to the aromatase inhibitor exemestane. Estrogen receptor positive.
Recommended Growing Conditions Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 0.1 uM exemestane.
Notes Human breast cancer cell line derived from MCF-7 cells
Other related cell lines:
- LetR-1, LetR-2, LetR-3 and LetR-4 resistant to the non-steroidal AI letrozole
- ExeR-1, ExeR-2 and ExeR-3 resistant to the steroidal AI exemestane
- AnaR-1, AnaR-2, AnaR-3 and AnaR-4 resistant to the non-steroidal AI anastrozole

Passage 432 (AL3949, AL3950)
Cellosaurus ID CVCL_5A16

References: 2 entries

Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.


Add a reference

References: 2 entries

Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.


Add a reference

References: 2 entries

Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.


Add a reference


This reagent does not have any reviews at the moment.